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Abstract
 
Natural killer (NK) cells mediate bone marrow allograft rejection. However, the molecular
mechanisms underlying such a rejection remain elusive. In previous analyses, it has been shown
that NK cells recognize allogeneic target cells through Ly-49s and CD94/NKG2 heterodimers.
Here, we describe identification and characterization of a novel murine NK receptor, NKG2I,
belonging to the NKG2 family. NKG2I, which was composed of 226 amino acids, showed
 
 
 
40% homology to the murine NKG2D and CD94 in the C-type lectin domain. Flow cyto-
metric analysis with anti-NKG2I monoclonal antibody (mAb) revealed that expression of
NKG2I was largely confined to NK and NKT cells, but was not seen in T cells. Furthermore,
anti-NKG2I mAb inhibited NK cell–mediated cytotoxicity, whereas cross-linking of NKG2I
enhanced interleukin 2– and interleukin 12–dependent interferon-
 
 
 
 production. Similarly, the
injection of anti-NKG2I mAb before the allogeneic bone marrow transfer in vivo impinged on
the function of NKG2I, resulting in the enhanced colony formation in the spleen. NKG2I is a
novel activating receptor mediating recognition and rejection of allogeneic target cells.
Key words: C-type lectin family • NK cells • activating receptor • IFN-
 
  
 
• NKT cells
 
Introduction
 
NK cells act as a first line of defense in innate immunity
and also mediate rejection of allogeneic target cells, such as
BM allografts (1, 2). NK cell function is exquisitely con-
trolled by the orchestration of signals from stimulatory and
inhibitory NK receptors, which recognize MHC class
I–related molecules on target cells (3, 4). NK receptors
have been categorized into three groups based on their
structural and sequence homology. The first is the killer cell
inhibitory receptors, belonging to the Ig superfamily, which
are expressed in humans but not in rodents (5, 6). The sec-
ond group is the C-type lectinlike Ly-49 receptors present
solely in rodents (7). The third is the lectinlike homo- and
heterodimer receptors, consisting of CD94 and a member
of NKG2 family; they are observed both in humans and in
rodents (8–10). Killer cell inhibitory receptors and Ly-49s
recognize classical MHC class I molecules, whereas NKG2
family receptors bind nonclassical MHC class I molecules
(11–13).
Regarding the role of NK receptors in NK cell–mediated
allorejection, involvement of the NK receptors, such as
CD94 and Ly-49, has been reported. Blocking the function
of CD94 with anti-CD94 mAb enhances the in vitro cyto-
toxicity of C57BL/6 NK cells against BALB/c Con A lym-
phoblast target cells (14), implying that CD94, most likely
together with NKG2A, may recognize the Qa-1 on the
target cells. In addition, anti–Ly-49D mAb treatment results
in eradication of a Ly-49D
 
 
 
 subset in lethally irradiated
C57BL/6 mice that, in turn, abrogates the ability to reject
H-2D
 
d
 
 BM graft (15). In the present paper, we report
identification and characterization of a novel murine
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NKG2 family receptor, NKG2I. We show that NKG2I
acts as an activating receptor and mediates allorecognition
and subsequent cytotoxic activity.
 
Materials and Methods
 
Animals. 
 
C57BL/6, BALB/c, C3H/HeN, ICR nu/nu
mice, and Fisher rats were obtained from Charles River Labora-
tories. DBA/2Cr, AKR/N, (BALB/c 
 
 
 
 C57BL/6) F1, and 129/
svJ mice were obtained from SLC and Jackson Laboratory, re-
spectively. All experiments were performed in accordance with
our institutional guidelines.
 
Identification of NKG2I through the Library Subtraction. 
 
PCR-
Select cDNA subtraction kit (CLONTECH Laboratories, Inc.)
was used to generate a library enriched for genes expressed in
NKT cells over T cells. In brief, T cells were purified from the
spleen of J
 
 
 
281 knockout mice (16), and NKT cells were puri-
fied by FACSVantage™ cell sorter (Becton Dickinson) with
 
 
 
-galactosylceramide/CD1-d tetramer staining from the spleen
of C57BL/6 mice. Purity of sorted cells was estimated to be
 
 
 
98%. In subtraction, T cell cDNA was used as a tester,
whereas that of NKT cells was used as a driver. After subtrac-
tion, 1,000 clones were sequenced and analyzed by virtual
Northern blot analysis.
 
Generation of Anti-NKG2I Monoclonal Antibodies. 
 
Fisher rats
were injected with a fusion protein consisting of the extracellular
portion of NKG2I and the Fc region of the human immunoglob-
ulin. Spleen cells were fused to the SP2/O-Ag14 fusion partner.
Hybridoma supernatants were screened for the staining ability of
NKG2I-transfected COS7 cells by flow cytometric analysis. Five
clones were established as follows: 3G7 (IgG1/
 
 
 
), 5C6 (IgG1/
 
 
 
),
7E8 (IgG2a/
 
 
 
), 9D5 (IgG2a/
 
 
 
), and 9F2 (IgG2a/
 
 
 
). The mAbs
were purified from ascites with protein G–Sepharose 4B and con-
jugated with biotin, FITC, and Cy5 with commercial kits.
 
Antibodies and cDNA.
 
Anti-NKG2D antibody, murine
CD94, NKG2C, E, D, DAP12, and DAP10 cDNA were pro-
vided by D.H. Raulet (University of California, Berkeley, Berke-
ley, CA). All other antibodies were obtained from BD Biosciences.
 
NK Cell Preparation and Stimulation by Anti-NKG2I mAb.
 
Splenic NK cells were enriched with anti-DX5 Ab using the Au-
toMACS™ (Miltenyi Biotec). For stimulation experiments, NK
cells were further purified as NK1.1
 
 
 
CD3
 
 
 
 cells to 
 
 
 
90% by de-
pleting CD4
 
 
 
, CD8
 
 
 
, CD3
 
 
 
, Gr-1
 
 
 
, Ter-119
 
 
 
, and CD19
 
 
 
 cells.
NK cells (10
 
5
 
 cells/well) were incubated for 24 h with or without
IL-2 and IL-12 in 96-well plates precoated with 10 
 
 
 
g/ml of
mAb, and the concentration of IFN-
 
 
 
 was measured by ELISA.
 
Cytotoxic Assay against Con A Lymphoblasts. 
 
Con A lympho-
blasts were generated by stimulation of spleen cells with 2 
 
 
 
g/ml
Con A (Sigma-Aldrich) for 48 h. Cytotoxic activities of IL-2–
expanded NK cells (cultured for 1 wk) against Con A lympho-
blasts were measured by a standard 
 
51
 
Cr release assay. The specific
lysis was calculated as follows: percent-specific lysis 
 
 
 
 
 
51
 
Cr cpm
[(experimental release 
 
 
 
 spontaneous release)/(maximum re-
lease 
 
 
 
 spontaneous release)] 
 
 
 
 100.
 
Biochemistry. 
 
IL-2–expanded NK cells were surface labeled
with 
 
125
 
I (Amersham Biosciences) using lactoperoxidase and lysed
with buffer (1% NP-40, 50 mM Tris, 150 mM NaCl, 1 mM
EDTA, and the protease inhibitor cocktail). The cell lysates were
incubated with the 7E8-coated protein G–Sepharose 4 FF (Am-
ersham Biosciences) and washed extensively. The samples were
separated on an SDS-PAGE, and bands were visualized using the
Bio Image Analyser (model BAS2500; Fuji Film).
 
Assay for BM Engraftment. 
 
Recipient C57BL/6 or (BALB/c 
 
 
 
C57BL/6) F1 mice irradiated at 9.5 Gy were received intrave-
nously with BALB/c or C57BL/6 BM cells. Spleen was removed
and fixed with the Bouin’s fixative on day 8, and the colony
number was counted.
 
GenBank Accession No. 
 
The NKG2I sequence has been de-
posited in GenBank/EMBL/DDBJ under accession no. AF306663.
 
Online Supplemental Material.
 
Table S1 summarizes the results
of cDNA subtraction (NKT vs. T cells), and Figs. S1 and S2
show the control experiments using anti–asialo GM1 and anti-
NKG2I. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20030851/DC1.
 
Results and Discussion
 
A Novel NK Receptor Belonging to NKG2 Family.
 
NKG2I was originally identified as a gene expressed prefer-
entially in NKT cells over T cells by subtractive hybridiza-
tion. Analysis of subtracted cDNA revealed that NK recep-
tors, such as NKG2A/B, NKRP1-C, and NKG2D, were
preferentially expressed in NKT cells (Table S1, available at
http://www.jem.org/cgi/content/full/jem.20030851/DC1).
A novel clone, preferentially expressed in NK and NKT
cells, showed an extensive homology to the NK receptors
and was subjected to further analysis (Figs. 1 and 2 A).
Putative proteins deduced from the nucleotide sequence
consisted of 226 amino acids with four structural domains
as follows: cytoplasmic (1-68), transmembrane (69-93),
stalk (94-109), and C-type lectin domain (CTLD; 110-
226) (Fig. 2 A). Sequence comparison indicated that
NKG2I was a novel NK receptor belonging to the NKG2
family. In fact, the CTLD within NKG2I showed 
 
 
 
40%
homology to that of murine NKG2D and CD94. More-
over, the residues in NKG2I, which may be engaged in
disulfide bond formation (Fig. 2 A, closed circles) and in
receptor dimerization (Fig. 2 A, closed circles and arrow-
heads), are readily inferred from the crystal structures of
CD94 and NKG2D (17, 18). These data suggest that the
CTLD in NKG2I possesses a higher order structure similar
to CD94 and NKG2D. Nevertheless, NKG2I lacks any
signaling motifs and positively charged amino acids in its
putative transmembrane region, which are required for as-
sociation with adaptor molecules such as Fc
 
 
 
RI
 
 
 
, CD3
 
 
 
,
DAP10, and DAP12 (Fig. 2 A; references 19, 20).
Ligands for other members of the murine NKG2 recep-
tors are MHC class I–related molecules as follows: Qa-1 for
Figure 1. Preferential expression
of NKG2I in NK and NKT cells
over T cells. NKG2I expression was
assessed by RT-PCR.  -actin serves
as input cDNA control. Threefold
serial dilution of cDNA was used. 
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CD94/NKG2 heterodimers (21, 22) and Raes, H60, and
MULT1 for NKG2D homodimers (23–25). As NKG2I
exhibits little similarity in a putative ligand binding domain
to other NK receptors (Fig. 2 A, squares), it may recognize
ligands distinct from those aforementioned (17, 18). An
abundance of positively charged amino acids in the cyto-
plasmic domain of NKG2I points to the possibility that it
may associate with novel adaptors responsible for signal
transduction (Fig. 2 A, asterisks).
DNA sequence analysis of NKG2I in the National Cen-
ter for Biotechnology Information mouse genome database
revealed that NKG2I maps adjacent to the CD94/NKG2
gene cluster and between CD69 and CD94 in NK receptor
gene complex on murine chromosome 6 (Fig. 2 B). Curi-
ously, no human orthologue of NKG2I was found, sug-
gesting that this receptor may be unique to rodents.
 
Characterization of NKG2I by the mAbs. 
 
To character-
ize NKG2I, we established several mAbs specific for NKG2I
(Fig. 3 A). These mAbs stained NKG2I-transfected COS7
cells specifically, and did not cross react with CD94,
NKG2A/C/E, or NKG2D molecules (Fig. 3 A). Staining
with 3G7 mAb revealed that most NK (NK1.1
 
 
 
CD3
 
 
 
) cells
in the spleen (84%), BM (74%), and liver (77%) expressed
NKG2I (Fig. 3 B). NKG2I was also expressed on a subset of
NKT (NK1.1
 
 
 
CD3
 
 
 
) cells, the expression levels of which
varied significantly among tissues (ranging from 13 to 54%),
but was barely detected on T (NK1.1
 
 
 
CD3
 
 
 
) cells (Fig. 3 B).
Because the expression of NKG2 varies depending on
mouse strains (14), we examined whether this is also the
case for NKG2I. Flow cytometric analysis showed that
NKG2I as well as CD94 and NKG2A/C/E expressions
were found regardless of strains (Fig. 3 C, C57BL/6,
BALB/c, C3H/HeN, DBA/2Cr, AKR/N, and 129/svJ).
However, the expression level of NKG2I differed among
the strains, implying the “calibration” of this receptor (26).
Moreover, the cDNA sequence for NKG2I from these
strains revealed that they encoded an identical amino acid,
suggesting that NKG2I is an invariant molecule on NK
cells and exhibits an expression profile distinct from that of
Ly-49s, which carry allelic polymorphisms (27).
Biochemical analysis with 
 
125
 
I-labeled NK cells followed
by immunoprecipitation with anti-NKG2I mAb (7E8) re-
vealed that NKG2I migrated predominantly as a 
 
 
 
96-kD
protein under nonreducing conditions, whereas a prominent
Figure 2. Characterization of
NKG2I. (A) Alignment of the
murine NKG2 family NK recep-
tors and human CD94. The
amino acid sequences of the
murine NKG2 family receptors
and human CD94 are aligned
using the ClustalW algorithm.
Highly conserved residues are
displayed in the dark shaded
boxes and depicted as consensus
amino acids below the align-
ment. Similar amino acids are
shown in light shaded boxes and
are indicated with dots. The dot-
ted line indicates the predicted
transmembrane region using the
TMpred program in EMBnet
(http://www.ch.embnet.org). The
squares indicate the putative
ligand-binding site based on the
crystal structure of the human
CD94. The arrowheads show
the hydrophobic residues re-
sponsible for dimerization. The
closed circles indicate the cysteins
involved in inter- and/or intramo-
lecular disulfide bonding. The
asterisks exhibit the positively
charged amino acids in the cyto-
plasmic domain. (B) Genomic
map of the murine NK gene
complex. The map is presented
schematically based on the
mouse genome sequence from
the National Center for Biotech-
nology Information. The relative
location of the NKG2I is indi-
cated by the arrow. 
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48-kD band emerged under reducing conditions on an
SDS-PAGE (Fig. 3 D, arrowheads). This suggests that
NKG2I forms homo- or heterodimer-like other NKG2
family members (21, 23, 24). Because its predicted molecular
weight is 26,265, it is conceivable that NKG2I is covalently
modified, though its precise nature has yet to be examined.
Figure 3. Characterization of
anti-NKG2I monoclonal anti-
bodies. (A) Establishment of the
mAbs against NKG2I. COS7
cells were transiently transfected
with mock, NKG2I, murine
CD94, NKG2A/C with CD94,
NKG2E with DAP12, and
NKG2D with DAP10 cDNA
expression vector. Cells were
harvested 48 h later and incu-
bated with the biotin-conjugated
3G7, 5C6, 7E8, 9D5, 9F2, or
control rat IgG, followed by stain-
ing with the FITC-streptavidin
(thick histogram). For CD94,
NKG2A/C/E, and NKG2D
transfectants, cells were incu-
bated with the biotin-conjugated
anti-CD94 mAb or with the
anti-NKG2A/C/E or anti-
NKG2D mAb as positive control
(P, thick histogram). Background
staining is shown as thin histo-
grams. (B) Expression of NKG2I
in the various lymphoid subsets.
Spleen, liver mononuclear cells,
thymocytes, and BM cells from
C57BL/6 mice were stained
with the FITC–anti-NKG2I
(3G7), PE-NK1.1, and Cy5–
anti-CD3. The expression of
NKG2I in the gated lymphoid
subsets for NK (NK1.1 CD3 ),
NKT (NK1.1 CD3 ), or T
(NK1.1 CD3 ) cells is shown as
histogram (thick lines) overlaid
with the background staining
(thin lines). The percentage of
NKG2I  cells in each lymphoid
subset is shown. (C) Expression
of the NKG2I, CD94, and
NKG2A/C/E in the various
strains of mice. Spleen cells from
the different mouse strains were
stained with PE-DX5 together
with biotin–anti-NKG2I (3G7),
anti-CD94, or anti-NKG2A/
C/E mAb followed by FITC-
streptavidin. Percentage of cells
in each subset is shown. (D)
NKG2I exists as a dimer with
the disulfide bond. C57BL/6
NK cells expanded with IL-2
were surface labeled with 125I
and immunoprecipitated with
the anti-NKG2I mAb (7E8) or
rat IgG2a. Immunoprecipitated
proteins were separated on an
SDS-PAGE under nonreducing
(in the absence of 2-mercapto-
ethanol [ 2ME]) or reducing
(in the presence of 2-mercapto-
ethanol [ 2ME]) conditions,
and visualized with BAS2500. 
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NKG2I Acts as an Activating Receptor in Allorejection.
 
Given that NKG2I is expressed predominantly in NK cells
(Fig. 3 B) and that CD94, which is quite similar to NKG2I,
is implicated in recognition of allogeneic target cells (14),
we hypothesized that NKG2I also plays a role in NK cell–
mediated allorecognition and subsequent cytotoxic activity.
Because activating signals elicited from NK receptors often
lead to cytokine production and/or activation of cytotoxic-
ity (28), the function of NKG2I was assessed by measuring
IFN-
 
 
 
 production (Fig. 4 A). Cross-linking of NKG2I
with 3G7 mAb led to induction of IFN-
 
 
 
 in the presence
of either IL-2 or IL-12 in a cytokine dose-dependent man-
ner and their synergistic effects were observed (Fig. 4 A,
right). These results indicate that NKG2I cross-linking en-
hances the extent of IL-2– and IL-12–elicited signaling
leading to IFN-
 
 
 
 production. Thus, NKG2I may serve as
an activating NK receptor.
We explored the function of NKG2I through an in vitro
cytolytic assay with 3G7 mAb (Fig. 4 B). C57BL/6 NK
cells lysed allogeneic BALB/c but not syngeneic C57BL/6
Con A lymphoblast target cells (Fig. 4 B). In contrast, treat-
ment of C57BL/6 NK cells with 3G7 mAb inhibited cy-
tolytic activity against BALB/c target cells significantly,
whereas control Ab showed little effect (Fig. 4 B, left).
Allogeneic BM cell transplantation experiments further
confirmed these results (Fig. 4 C). BALB/c BM cells ad-
ministrated into lethally irradiated C57BL/6 mice (BALB/c
into C57BL/6) were rejected in a manner dependent on
Figure 4. NKG2I functions as an activating
NK receptor in allograft rejection. (A) IFN- 
production upon cross-linking of NKG2I in
NK cells. NK cells from C57BL/6 spleen were
incubated in the presence of IL-2, IL-12, or IL-2/
IL-12 in the plate immobilized with 3G7 or rat
IgG1. Control experiments were done without
any antibody. The concentrations of IFN-  in
the culture supernatant are shown. Data are
indicated as mean   SD from three indepen-
dent experiments. (B) 3G7 mAb inhibits the
cytotoxicity of NK cells against the allogeneic
target cells. The cytolytic activity of C57BL/6
NK cells expanded with IL-2 was determined
in the presence of 10  g/ml of 3G7 mAb or
control rat IgG1. Control experiments were
done without any antibody. Con A lympho-
blasts prepared from BALB/c (left) or C57BL/6
(right) mice were used as target cells. Data are
shown as mean   SD from three independent
experiments (n   6/experiment). *, P   0.05 as
compared 3G7 mAb versus rat IgG1 at the indi-
cated E/T ratio. (C) Blocking the NKG2I
function compromises rejection of the allogeneic
BM cell transplantation. Responder C57BL/6
or (BALB/c   C57BL/6) F1 mice were treated
with 100  g of 3G7 mAb or rat IgG before BM
transplantation with 3   106 cells (for C57BL/6
recipients) or 0.1   106 cells (for F1 recipients)
from BALB/c or C57BL/6, and received the
same amount of each of the Abs on days 3 and
6. The number of colonies in the spleen of the
recipient mice (n   5) was counted 8 d after
BM transfer. The error bars represent the standard
deviation, and representative data from three
independent experiments are shown. (D) Block-
ing the function of NKG2I does not interfere
with the expression of other NK receptors. The
effect of 3G7 mAb on the expression of other
NK receptors relevant to the allorejection was
evaluated by flow cytometric analysis on NK
cells. C57BL/6 mice were left untreated (top)
or treated with 100  g/body of 3G7 (bottom)
for 1 h. NK (NK1.1 CD3 ) cells were stained
with the biotin–anti-NKG2I (7E8), biotin–
anti-CD94, biotin–anti-NKG2A/C/E, bio-
tin–anti-Ly49A, biotin–anti-Ly49C/I, or FITC–
anti-Ly49D, respectively. Biotin-conjugated Ab
was visualized with FITC-streptavidin. Expression
of each NK receptor is shown as histogram
(thick lines) overlaid with background staining
(thin lines). 
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NK cells, and no colony derived from the transplanted cells
appeared in the spleen of recipient mice as reported (Fig. 4
C, left; reference 29). In contrast, administration of 3G7
mAb but not the control anti–rat IgG Ab into the recipient
C57BL/6 mice before BALB/c BM transfer suppressed the
rejection of BALB/c BM grafts and resulted in a significant
number of colony formations in the spleen (Fig. 4 C, left).
Similarly, (BALB/c 
 
 
 
 C57BL/6) F1 mice as a recipient,
whose T cells are tolerant to the parent BALB/c, showed
significantly impaired rejection of BALB/c BM cells
(BALB/c into F1) in the presence of 3G7 mAb (Fig. 4 C,
middle). In contrast, no effects were observed in the synge-
neic BM transplantation (Fig. 4 C, right, C57BL/6 into
C57BL/6). These results indicate that NKG2I on NK cells
recognizes putative ligands present on allogeneic BM cells
and induces signals leading to the rejection of allografts.
It should be mentioned that administration of anti-
NK1.1, anti–asialo GM1, or anti–Ly-49D mAb also abro-
gated the rejection of allogeneic BM grafts (Fig. S1,
available at http://www.jem.org/cgi/content/full/jem.
20030851/DC1), but these effects were primarily due to
the depletion of NK cells expressing these molecules (15,
29). On the other hand, 3G7 mAb treatment did not
change the number of NK cells in vivo (Fig. S2, available at
http://www.jem.org/cgi/content/full/jem.20030851/DC1).
More importantly, 3G7 mAb treatment did not alter the
expression of other NK receptors, such as CD94, NKG2A/
C/E, Ly-49A, Ly-49C/I, and Ly-49D, under the condi-
tions that NKG2I expression was rapidly down-regulated
in vivo (Fig. 4 D). These results suggest that allogeneic rec-
ognition and subsequent activation of NK cells leading to
cytotoxic activity against allogeneic BM cells is attributed
to NKG2I but not to modulation of other NK receptor ex-
pression.
In summary, we have identified and characterized a novel
activating NK receptor that plays a crucial role in allograft
rejection. Identification of the cognate ligands and elucida-
tion of the signaling pathway of NKG2I will shed light on
mechanisms underlying allogeneic recognition and rejection.
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